Explore

Trendline Trendline
Palatin Reports Reduced Net Loss and Advances Obesity Programs

Palatin Reports Reduced Net Loss and Advances Obesity Programs

Palatin Reports Reduced Net Loss and Advances Obesity Programs
Trendline Trendline
Palatin Technologies Reports Q3 2026 Financial Results and Business Update

Palatin Technologies Reports Q3 2026 Financial Results and Business Update

Palatin Technologies Reports Q3 2026 Financial Results and Business Update
Trendline Trendline
Palatin Technologies Reports Q3 2026 Financial Results and Business Progress

Palatin Technologies Reports Q3 2026 Financial Results and Business Progress

Palatin Technologies Reports Q3 2026 Financial Results and Business Progress
Trendline Trendline
Galapagos Rebrands as Lakefront Biotherapeutics Amid Strategic Shift

Galapagos Rebrands as Lakefront Biotherapeutics Amid Strategic Shift

Galapagos Rebrands as Lakefront Biotherapeutics Amid Strategic Shift
Trendline Trendline
AstraZeneca's Hypoparathyroidism Drug Faces Efficacy Challenges in Phase 3 Trial

AstraZeneca's Hypoparathyroidism Drug Faces Efficacy Challenges in Phase 3 Trial

AstraZeneca's Hypoparathyroidism Drug Faces Efficacy Challenges in Phase 3 Trial
Trendline Trendline
Savara Reports Increased Losses in Q1 2026 Amid Regulatory Milestones for MOLBREEVI

Savara Reports Increased Losses in Q1 2026 Amid Regulatory Milestones for MOLBREEVI

Savara Reports Increased Losses in Q1 2026 Amid Regulatory Milestones for MOLBREEVI
Trendline Trendline
Hiteck and LexBio Unveil HT016 VAV1 Molecular Glue Degrader at AAI 2026

Hiteck and LexBio Unveil HT016 VAV1 Molecular Glue Degrader at AAI 2026

Hiteck and LexBio Unveil HT016 VAV1 Molecular Glue Degrader at AAI 2026
Trendline Trendline
Savara Inc. to Participate in BioConnect Investor Conference, Highlighting Rare Respiratory Disease Focus

Savara Inc. to Participate in BioConnect Investor Conference, Highlighting Rare Respiratory Disease Focus

Savara Inc. to Participate in BioConnect Investor Conference, Highlighting Rare Respiratory Disease Focus
Trendline Trendline
MacroGenics Sells Maryland Drug Manufacturing Plant to Bora for $122.5 Million

MacroGenics Sells Maryland Drug Manufacturing Plant to Bora for $122.5 Million

MacroGenics Sells Maryland Drug Manufacturing Plant to Bora for $122.5 Million
Trendline Trendline
AI and Biotechnology Convergence Drives Personalized Medicine Advancements

AI and Biotechnology Convergence Drives Personalized Medicine Advancements

AI and Biotechnology Convergence Drives Personalized Medicine Advancements
Trendline Trendline
AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials
Trendline Trendline
Arrowhead Pharmaceuticals Transitions to Fully Integrated Company Under CEO Christopher Anzalone

Arrowhead Pharmaceuticals Transitions to Fully Integrated Company Under CEO Christopher Anzalone

Arrowhead Pharmaceuticals Transitions to Fully Integrated Company Under CEO Christopher Anzalone